Print Page | Sign In | Join Today
News & Press: Company News

CEL-SCI Selected by NIH to Showcase Its Technology at BIO International Convention

Friday, March 8, 2019  
Share |
CEL-SCI Corporation announced it has been selected by the U.S. National Institutes of Health (NIH) for sponsorship to exhibit and showcase its presentation for its LEAPS technology at the BIO International Convention, to be held June 3-6, 2019 in Philadelphia.

LEAPS, which is currently being developed as a therapeutic vaccine for rheumatoid arthritis under a $1.5 million SBIR/STTR grant from the NIH, will be featured at the convention’s Innovation Zone, a turn-key exhibit space dedicated to showcasing select NIH SBIR/STTR awardees.

“We are honored that our LEAPS technology has been selected by the NIH to be showcased at Bio International. Through the NIH’s commitment to assist awardees like CEL-SCI in our path to commercialization, we expect LEAPS will benefit from the premier visibility it will receive from potential development partners and investors at this year’s BIO International Convention,” stated CEL-SCI CEO Geert Kersten.
Upon completion of preclinical and Investigational New Drug (IND) enabling studies for the LEAPS-based rheumatoid arthritis vaccine candidate CEL-4000, CEL-SCI intends to file an IND application with the U.S. Food and Drug Administration.

Our Premium Partners

Sign up for our newsletter
800 E. Leigh St.  |  Richmond, Va 23219-1534  |  PH: 804.643.6360  |  Email Us
Stay Connected